STI diagnosis at centre of new UK focus on public health
This article was originally published in Clinica
Executive Summary
A pledge to extend chlamydia screening across England and improve access to specialised genitourinary care are two of the more tangible initiatives contained in the UK's White Paper on Public Health, published last week. The document also puts flesh on the bones of the healthcare restructuring plans announced in the government's Arm's Length Bodies review last July, by setting out some of the quality standards, responsibilities and targets attached to these historic reforms.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.